← Retour au Screener

Sector: Santé
Open in Terminal → AMWLLive chart · Key metrics · News · Smart money

Amwell

AMWL Micro Cap

Healthcare · Health Information Services

Mis à jour: Jun 18, 2026, 22:21 UTC

7,36 €
-0.82% aujourd'hui
52W: 3,24 € – 8,69 €
52W Low: 3,24 € Position: 75.5% 52W High: 8,69 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
0.59x
Cours/Ventes
EV/EBITDA
0.41x
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
123 M €
Capitalisation boursière
Croissance du CA
-17.9%
Croissance du CA sur un an
Marge bénéficiaire
-37.02%
Marge nette
ROE
-31.84%
Rentabilité des capitaux propres
Beta
1.7
Sensibilité au marché
Positions vendeuses
1.37%
% du flottant vendu à découvert
Volume moyen
74,112
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Conserver
5 analysts
Avg. Price Target
6,55 €
-11.03% upside
Target Range
5,67 € – 7,85 €

About the Company

Sector: Healthcare Industry: Health Information Services Country: United States Employees: 562 Exchange: NYQ

Amwell en bref

Amwell (AMWL) is currently trading at 7,36 € with a market capitalization of 123 M €. The 52-week range spans from 3,24 € to 8,69 €; the current price is 15.4% below the yearly high. Year-over-year revenue growth stands at -17.9%.

💰 Dividende

Amwell currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

5 analystes évaluent Amwell (AMWL) au consensus : Conserver. L'objectif de cours moyen est de 6,55 €, soit un potentiel de -11.03% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 5,67 € à 7,85 €.

Amwell : la thèse d'investissement en détail

Amwell (AMWL) operates in the Healthcare — specifically Health Information Services — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Revenue is contracting at -17.9% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

Valorisation en contexte

The EV/EBITDA multiple of 0.41x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

Thèse d'investissement : forces et faiblesses

Points forts
  • Marge brute élevée de 53.8% — signe d'un pouvoir de fixation des prix
  • Bilan solide avec faible endettement (D/E 1.65)
Points faibles
  • CA en contraction (-17.9% sur un an)
  • Actuellement non rentable
  • Free cash flow négatif

Aperçu technique

MM 50 jours
6,48 €
+13.46% vs. cours
MM 200 jours
5,03 €
+46.35% vs. cours
Sous le plus haut 52s
−15.4%
8,69 €
Au-dessus du plus bas 52s
+127.2%
3,24 €

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

Risque de marché (Bêta)
1.7 · Élevé
Évolue plus que le marché global
Positions vendeuses
1.37% · Faible
% du flottant vendu à découvert
Dette/Capitaux propres
1.65 · Faible
Dette totale / capitaux propres

The data points to above-average price swings.

Trading Data

50-Day MA: 6,48 €
200-Day MA: 5,03 €
Volume: 82,881
Avg. Volume: 74,112
Short Ratio: 2.47
P/B Ratio: 0.62x
Debt/Equity: 1.65x
Free Cash Flow: -10 275 760 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Amwell?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut